Home/Pipeline/Ferabright (ferumoxytol injection)

Ferabright (ferumoxytol injection)

MRI of the brain in adults with known or suspected malignant neoplasms

ApprovedActive

Key Facts

Indication
MRI of the brain in adults with known or suspected malignant neoplasms
Phase
Approved
Status
Active
Companies

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a US-based, private specialty pharma company founded in 2014, targeting overlooked patient needs with a portfolio of over 50 approved products. It leverages a 'Next-Gen Commercial Model' utilizing data, analytics, and AI-driven digital tools to enhance commercial reach and stakeholder engagement. The company has a significant global footprint and recently launched new proprietary products like Ferabright and ARYNTA, signaling a strategic shift beyond pure generics into branded specialty pharmaceuticals.

View full company profile

About NextSource Pharma

Azurity Pharmaceuticals is a US-based, private specialty pharma company founded in 2018, with a core mission of serving overlooked patients through customized drug formulations. It has built a commercial-stage portfolio of over 50 products, spanning key therapeutic areas, and utilizes a Next-Gen Commercial Model powered by data, analytics, and AI-driven tools. The company has a global footprint in over 50 countries and recently launched new products like Ferabright and Arynta, demonstrating ongoing pipeline execution and commercial growth.

View full company profile